[{"id":"4827359c-749f-4084-aeb0-6c8f0ce2d993","acronym":"dendritic cell","url":"https://clinicaltrials.gov/study/NCT07479667","created_at":"2026-03-28T01:39:16.862Z","updated_at":"2026-03-28T01:39:16.862Z","phase":"Phase 1","brief_title":"An Antibody-armored Dendritic Cell in Patients With Solid Tumors","source_id_and_acronym":"NCT07479667 - dendritic cell","lead_sponsor":"Shanghai Cell Therapy Group Co.,Ltd","biomarkers":" KRAS • TP53","pipe":"","alterations":" ","tags":["KRAS • TP53"],"overall_status":"Recruiting","enrollment":" Enrollment 8","initiation":"Initiation: 02/05/2026","start_date":" 02/05/2026","primary_txt":" Primary completion: 12/31/2028","primary_completion_date":" 12/31/2028","study_txt":" Completion: 06/30/2029","study_completion_date":" 06/30/2029","last_update_posted":"2026-03-18"},{"id":"08b2bc8f-c536-4ab4-95bd-8afe3b23bcd7","acronym":"NRG-GY026","url":"https://clinicaltrials.gov/study/NCT05256225","created_at":"2022-02-25T17:52:52.661Z","updated_at":"2025-02-25T12:28:40.900Z","phase":"Phase 2/3","brief_title":"Testing the Addition of Trastuzumab or Trastuzumab/Pertuzumab to the Usual Chemotherapy for HER2 Positive Endometrial Cancer","source_id_and_acronym":"NCT05256225 - NRG-GY026","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" HER-2 • TP53","pipe":" | ","alterations":" HER-2 positive • HER-2 amplification","tags":["HER-2 • TP53"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • HER-2 amplification"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Herceptin (trastuzumab) • carboplatin • paclitaxel • Perjeta (pertuzumab) • Phesgo (pertuzumab/trastuzumab/hyaluronidase-zzxf)"],"overall_status":"Recruiting","enrollment":" Enrollment 525","initiation":"Initiation: 11/16/2022","start_date":" 11/16/2022","primary_txt":" Primary completion: 10/31/2027","primary_completion_date":" 10/31/2027","study_txt":" Completion: 10/31/2027","study_completion_date":" 10/31/2027","last_update_posted":"2025-02-24"},{"id":"5d9596a1-d384-4d3e-99e8-4001de1a4302","acronym":"EVOLVE CLL/SLL","url":"https://clinicaltrials.gov/study/NCT04269902","created_at":"2021-01-18T20:44:42.322Z","updated_at":"2025-02-25T12:27:29.630Z","phase":"Phase 3","brief_title":"Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study","source_id_and_acronym":"NCT04269902 - EVOLVE CLL/SLL","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" TP53 • IGH","pipe":" | ","alterations":" TP53 mutation • IGH mutation","tags":["TP53 • IGH"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 mutation • IGH mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Venclexta (venetoclax) • Gazyva (obinutuzumab)"],"overall_status":"Recruiting","enrollment":" Enrollment 247","initiation":"Initiation: 03/02/2021","start_date":" 03/02/2021","primary_txt":" Primary completion: 10/01/2028","primary_completion_date":" 10/01/2028","study_txt":" Completion: 10/01/2028","study_completion_date":" 10/01/2028","last_update_posted":"2025-02-24"},{"id":"9e19f934-321f-4e6c-b066-71f0217f0bae","acronym":"","url":"https://clinicaltrials.gov/study/NCT03041688","created_at":"2021-01-18T14:58:33.453Z","updated_at":"2025-02-25T12:26:38.524Z","phase":"Phase 1","brief_title":"Testing a New Chemotherapy Drug, KRT-232 (AMG-232) in Combination With Decitabine and Venetoclax in Patients With Acute Myeloid Leukemia","source_id_and_acronym":"NCT03041688","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" TP53 • CD4","pipe":" | ","alterations":" TP53 mutation • Chr del(17p) • TP53 wild-type","tags":["TP53 • CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 mutation • Chr del(17p) • TP53 wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Venclexta (venetoclax) • azacitidine • decitabine • navtemadlin (KRT-232)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 58","initiation":"Initiation: 02/08/2018","start_date":" 02/08/2018","primary_txt":" Primary completion: 06/30/2026","primary_completion_date":" 06/30/2026","study_txt":" Completion: 06/30/2026","study_completion_date":" 06/30/2026","last_update_posted":"2025-02-24"},{"id":"c5baf3d3-95f8-46cc-89ee-2ac65d9ade70","acronym":"","url":"https://clinicaltrials.gov/study/NCT06023641","created_at":"2023-09-05T18:12:33.949Z","updated_at":"2025-02-25T12:29:46.532Z","phase":"Phase 1/2","brief_title":"Treatment of Newly Diagnosed Rhabdomyosarcoma Using Molecular Risk Stratification and Liposomal Irinotecan Based Therapy in Children With Intermediate and High Risk Disease","source_id_and_acronym":"NCT06023641","lead_sponsor":"St. Jude Children's Research Hospital","biomarkers":" TP53 • FOXO1 • MYOD1","pipe":" | ","alterations":" TP53 mutation","tags":["TP53 • FOXO1 • MYOD1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e temozolomide • cyclophosphamide • vincristine • vinorelbine tartrate • dactinomycin • Onivyde (nanoliposomal irinotecan) • Navelbine oral (vinorelbine tartrate oral) • Neupogen (filgrastim)"],"overall_status":"Recruiting","enrollment":" Enrollment 100","initiation":"Initiation: 03/13/2024","start_date":" 03/13/2024","primary_txt":" Primary completion: 10/01/2034","primary_completion_date":" 10/01/2034","study_txt":" Completion: 10/01/2037","study_completion_date":" 10/01/2037","last_update_posted":"2025-02-24"},{"id":"21be25ed-db5c-4f88-af53-6dabef3b154a","acronym":"SUMIT-ELA","url":"https://clinicaltrials.gov/study/NCT05963997","created_at":"2023-07-27T17:09:07.832Z","updated_at":"2025-02-25T13:41:37.681Z","phase":"Phase 1/2","brief_title":"A Study of Samuraciclib and Elacestrant in Participants with Metastatic or Locally Advanced HR+/HER2-negative Breast Cancer","source_id_and_acronym":"NCT05963997 - SUMIT-ELA","lead_sponsor":"Carrick Therapeutics Limited","biomarkers":" HER-2 • ER • TP53 • CDK4","pipe":" | ","alterations":" TP53 mutation • ER positive • HER-2 negative • HER-2 negative + ER positive • HER-2 negative + ER positive + ESR1 mutation","tags":["HER-2 • ER • TP53 • CDK4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 mutation • ER positive • HER-2 negative • HER-2 negative + ER positive • HER-2 negative + ER positive + ESR1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Orserdu (elacestrant) • samuraciclib (CT7001)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 49","initiation":"Initiation: 10/09/2023","start_date":" 10/09/2023","primary_txt":" Primary completion: 12/23/2025","primary_completion_date":" 12/23/2025","study_txt":" Completion: 12/23/2025","study_completion_date":" 12/23/2025","last_update_posted":"2025-02-21"},{"id":"3f832c54-ae2b-45dd-b72a-df4624a79314","acronym":"SUMIT-BC","url":"https://clinicaltrials.gov/study/NCT05963984","created_at":"2023-07-27T17:09:07.566Z","updated_at":"2025-02-25T13:41:37.189Z","phase":"Phase 2","brief_title":"A Study of Samuraciclib in Combination With Fulvestrant in Metastatic or Locally Advanced Breast Cancer in Adult Participants","source_id_and_acronym":"NCT05963984 - SUMIT-BC","lead_sponsor":"Carrick Therapeutics Limited","biomarkers":" HER-2 • ER • TP53 • CDK4","pipe":" | ","alterations":" TP53 mutation • ER positive • HER-2 negative • HER-2 negative + ER positive","tags":["HER-2 • ER • TP53 • CDK4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 mutation • ER positive • HER-2 negative • HER-2 negative + ER positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e fulvestrant • samuraciclib (CT7001)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 60","initiation":"Initiation: 12/14/2023","start_date":" 12/14/2023","primary_txt":" Primary completion: 06/30/2025","primary_completion_date":" 06/30/2025","study_txt":" Completion: 12/31/2025","study_completion_date":" 12/31/2025","last_update_posted":"2025-02-21"},{"id":"4122017d-37fb-40e3-a993-7bf5c634b108","acronym":"","url":"https://clinicaltrials.gov/study/NCT01443468","created_at":"2021-01-18T05:59:05.738Z","updated_at":"2025-02-25T13:39:04.583Z","phase":"","brief_title":"Clinical and Genetic Studies of Li-Fraumeni Syndrome","source_id_and_acronym":"NCT01443468","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" TP53","pipe":" | ","alterations":" TP53 mutation","tags":["TP53"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 mutation"],"overall_status":"Recruiting","enrollment":" Enrollment 5000","initiation":"Initiation: 01/17/2012","start_date":" 01/17/2012","primary_txt":"","primary_completion_date":"","study_txt":"","study_completion_date":"","last_update_posted":"2025-02-21"},{"id":"593b542b-470d-465e-ae6a-8f9b079a6849","acronym":"ALLIANCE-ABTC-1604","url":"https://clinicaltrials.gov/study/NCT03107780","created_at":"2021-01-18T15:18:36.892Z","updated_at":"2025-02-25T13:48:22.462Z","phase":"Phase 1","brief_title":"Testing the Ability of AMG 232 (KRT 232) to Get Into the Tumor in Patients With Brain Cancer","source_id_and_acronym":"NCT03107780 - ALLIANCE-ABTC-1604","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" TP53 • MGMT","pipe":" | ","alterations":" TP53 wild-type","tags":["TP53 • MGMT"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e navtemadlin (KRT-232)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 32","initiation":"Initiation: 07/09/2018","start_date":" 07/09/2018","primary_txt":" Primary completion: 03/21/2019","primary_completion_date":" 03/21/2019","study_txt":" Completion: 02/07/2026","study_completion_date":" 02/07/2026","last_update_posted":"2025-02-21"},{"id":"907c18db-1f38-4071-a1e3-b3af86377f13","acronym":"","url":"https://clinicaltrials.gov/study/NCT05941520","created_at":"2023-07-12T16:10:13.477Z","updated_at":"2025-02-25T13:49:53.635Z","phase":"Phase 2","brief_title":"Acolbifene Versus Low Dose Tamoxifen for the Prevention of Breast Cancer in Premenopausal Women at High Risk for Development of Breast Cancer","source_id_and_acronym":"NCT05941520","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" TP53 • PTEN • ATM • NF1 • MSH6 • CDH1 • CHEK2 • BRIP1 • RAD51C • RAD51D • BARD1 • NBN • AGR2","pipe":" | ","alterations":" TP53 mutation • ATM mutation • CHEK2 mutation • BRIP1 mutation • RAD51C mutation • RAD51D mutation • BARD1 mutation","tags":["TP53 • PTEN • ATM • NF1 • MSH6 • CDH1 • CHEK2 • BRIP1 • RAD51C • RAD51D • BARD1 • NBN • AGR2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 mutation • ATM mutation • CHEK2 mutation • BRIP1 mutation • RAD51C mutation • RAD51D mutation • BARD1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e tamoxifen • acolbifene"],"overall_status":"Recruiting","enrollment":" Enrollment 80","initiation":"Initiation: 08/23/2024","start_date":" 08/23/2024","primary_txt":" Primary completion: 08/23/2027","primary_completion_date":" 08/23/2027","study_txt":" Completion: 09/01/2028","study_completion_date":" 09/01/2028","last_update_posted":"2025-02-21"},{"id":"e17de7f3-6ed2-44ac-8c1d-acf78b25a29e","acronym":"NCI-2017-02296","url":"https://clinicaltrials.gov/study/NCT03375307","created_at":"2021-01-18T16:39:30.359Z","updated_at":"2025-02-25T13:39:36.028Z","phase":"Phase 2","brief_title":"Testing Olaparib in Patients With Advanced or Metastatic (Cancer That Has Spread) Bladder Cancer and Other Genitourinary Tumors With DNA-Repair Genetic Changes","source_id_and_acronym":"NCT03375307 - NCI-2017-02296","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" TP53 • TMB • ABL1 • MSI • STK11 • NPM1 • POLE • CCND1 • MLH1 • MSH6 • MSH2 • ATRX • CHEK2 • SMARCB1 • RAD51 • POLD1 • CHEK1 • BARD1 • FANCL • BRD4 • DOT1L • FANCE • FANCG • IKBKE • FANCC","pipe":" | ","alterations":" FANCG mutation","tags":["TP53 • TMB • ABL1 • MSI • STK11 • NPM1 • POLE • CCND1 • MLH1 • MSH6 • MSH2 • ATRX • CHEK2 • SMARCB1 • RAD51 • POLD1 • CHEK1 • BARD1 • FANCL • BRD4 • DOT1L • FANCE • FANCG • IKBKE • FANCC"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FANCG mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lynparza (olaparib)"],"overall_status":"Recruiting","enrollment":" Enrollment 150","initiation":"Initiation: 11/03/2020","start_date":" 11/03/2020","primary_txt":" Primary completion: 12/16/2025","primary_completion_date":" 12/16/2025","study_txt":" Completion: 12/16/2025","study_completion_date":" 12/16/2025","last_update_posted":"2025-02-21"},{"id":"168840e4-a367-4523-bec5-a87bb18a9b81","acronym":"NT-175-201","url":"https://clinicaltrials.gov/study/NCT05877599","created_at":"2023-05-26T15:07:05.809Z","updated_at":"2025-02-25T13:55:14.477Z","phase":"Phase 1","brief_title":"A Study of NT-175 in Adult Subjects With Unresectable, Advanced, and/or Metastatic Solid Tumors That Are Positive for HLA-A*02:01 and the TP53 R175H Mutation","source_id_and_acronym":"NCT05877599 - NT-175-201","lead_sponsor":"AstraZeneca","biomarkers":" TP53 • HLA-A","pipe":" | ","alterations":" TP53 mutation • HLA-A*02:01","tags":["TP53 • HLA-A"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 mutation • HLA-A*02:01"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • fludarabine IV • NT-175"],"overall_status":"Recruiting","enrollment":" Enrollment 162","initiation":"Initiation: 07/12/2023","start_date":" 07/12/2023","primary_txt":" Primary completion: 09/01/2028","primary_completion_date":" 09/01/2028","study_txt":" Completion: 08/01/2039","study_completion_date":" 08/01/2039","last_update_posted":"2025-02-20"},{"id":"a2748e44-3f76-4ef4-9c24-1b7476039a69","acronym":"","url":"https://clinicaltrials.gov/study/NCT05554393","created_at":"2022-09-26T14:56:10.693Z","updated_at":"2025-02-25T13:49:33.606Z","phase":"Phase 2","brief_title":"Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial)","source_id_and_acronym":"NCT05554393","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" TP53 • FLT3 • NPM1 • RUNX1 • ASXL1 • RARA • RUNX1T1 • PML • CEBPA","pipe":" | ","alterations":" TP53 mutation • FLT3-ITD mutation • NPM1 mutation • RUNX1 mutation • ASXL1 mutation • FLT3-TKD mutation","tags":["TP53 • FLT3 • NPM1 • RUNX1 • ASXL1 • RARA • RUNX1T1 • PML • CEBPA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 mutation • FLT3-ITD mutation • NPM1 mutation • RUNX1 mutation • ASXL1 mutation • FLT3-TKD mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Venclexta (venetoclax) • cytarabine • azacitidine • daunorubicin • Starasid (cytarabine ocfosfate)"],"overall_status":"Recruiting","enrollment":" Enrollment 153","initiation":"Initiation: 09/13/2024","start_date":" 09/13/2024","primary_txt":" Primary completion: 12/31/2025","primary_completion_date":" 12/31/2025","study_txt":" Completion: 12/31/2025","study_completion_date":" 12/31/2025","last_update_posted":"2025-02-20"},{"id":"5325032a-dfb5-4381-8e59-f5e1418ec3ae","acronym":"DASH","url":"https://clinicaltrials.gov/study/NCT04704661","created_at":"2021-01-19T20:51:17.334Z","updated_at":"2025-02-25T14:02:10.901Z","phase":"Phase 1","brief_title":"Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Patients With Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial","source_id_and_acronym":"NCT04704661 - DASH","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" HER-2 • TP53 • ATM • RAS • CD4","pipe":" | ","alterations":" HER-2 positive • TP53 mutation • HER-2 amplification • HER-2 expression • RAS mutation","tags":["HER-2 • TP53 • ATM • RAS • CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • TP53 mutation • HER-2 amplification • HER-2 expression • RAS mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Enhertu (fam-trastuzumab deruxtecan-nxki) • ceralasertib (AZD6738)"],"overall_status":"Recruiting","enrollment":" Enrollment 51","initiation":"Initiation: 08/09/2021","start_date":" 08/09/2021","primary_txt":" Primary completion: 03/31/2026","primary_completion_date":" 03/31/2026","study_txt":" Completion: 03/31/2026","study_completion_date":" 03/31/2026","last_update_posted":"2025-02-19"},{"id":"8061a0a4-90b7-438d-bd01-079e025dc238","acronym":"","url":"https://clinicaltrials.gov/study/NCT03113487","created_at":"2021-01-18T15:20:26.946Z","updated_at":"2025-02-25T14:01:16.153Z","phase":"Phase 2","brief_title":"P53MVA and Pembrolizumab in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer","source_id_and_acronym":"NCT03113487","lead_sponsor":"City of Hope Medical Center","biomarkers":" PD-L1 • TP53 • MUC16","pipe":" | ","alterations":" TP53 mutation","tags":["PD-L1 • TP53 • MUC16"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • p53MVA"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 29","initiation":"Initiation: 02/01/2018","start_date":" 02/01/2018","primary_txt":" Primary completion: 08/26/2022","primary_completion_date":" 08/26/2022","study_txt":" Completion: 06/03/2025","study_completion_date":" 06/03/2025","last_update_posted":"2025-02-19"},{"id":"4bdac475-2ce7-43c7-9fc6-1b82deed752b","acronym":"","url":"https://clinicaltrials.gov/study/NCT05376800","created_at":"2022-05-17T12:54:19.363Z","updated_at":"2025-02-25T14:08:51.835Z","phase":"Phase 1","brief_title":"A Study to Determine How BI 907828 (Brigimadlin) is Taken up in the Tumor (Phase 0) and to Determine the Highest Dose of BI 907828 (Brigimadlin) That Could be Tolerated (Phase 1a) in Combination With Radiation Therapy in People With a Brain Tumor Called Glioblastoma","source_id_and_acronym":"NCT05376800","lead_sponsor":"Boehringer Ingelheim","biomarkers":" TP53","pipe":" | ","alterations":" TP53 wild-type • IDH wild-type","tags":["TP53"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 wild-type • IDH wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e brigimadlin (BI 907828)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 24","initiation":"Initiation: 11/07/2022","start_date":" 11/07/2022","primary_txt":" Primary completion: 08/29/2025","primary_completion_date":" 08/29/2025","study_txt":" Completion: 08/29/2025","study_completion_date":" 08/29/2025","last_update_posted":"2025-02-18"},{"id":"e403d404-bc05-4817-9ff3-f97c2077e32b","acronym":"","url":"https://clinicaltrials.gov/study/NCT03449381","created_at":"2021-01-18T17:00:34.045Z","updated_at":"2025-02-25T14:15:08.572Z","phase":"Phase 1","brief_title":"This Study Aims to Find the Best Dose of BI 907828 (Brigimadlin) in Patients With Different Types of Advanced Cancer (Solid Tumors)","source_id_and_acronym":"NCT03449381","lead_sponsor":"Boehringer Ingelheim","biomarkers":" TP53 • MDM2","pipe":" | ","alterations":" TP53 wild-type","tags":["TP53 • MDM2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e brigimadlin (BI 907828)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 267","initiation":"Initiation: 06/20/2018","start_date":" 06/20/2018","primary_txt":" Primary completion: 06/30/2025","primary_completion_date":" 06/30/2025","study_txt":" Completion: 06/30/2025","study_completion_date":" 06/30/2025","last_update_posted":"2025-02-18"},{"id":"64ec7fee-f0ad-4556-bc3c-857c74e02812","acronym":"","url":"https://clinicaltrials.gov/study/NCT04145115","created_at":"2021-07-05T17:26:08.613Z","updated_at":"2025-02-25T14:07:33.392Z","phase":"Phase 2","brief_title":"A Study Testing the Effect of Immunotherapy (Ipilimumab and Nivolumab) in Patients With Recurrent Glioma With Elevated Mutational Burden","source_id_and_acronym":"NCT04145115","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" EGFR • TP53 • CDKN2A • TERT • CDKN2B • ATRX","pipe":" | ","alterations":" TP53 mutation • EGFR mutation • EGFR amplification • CDKN2A deletion • IDH wild-type","tags":["EGFR • TP53 • CDKN2A • TERT • CDKN2B • ATRX"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 mutation • EGFR mutation • EGFR amplification • CDKN2A deletion • IDH wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • Yervoy (ipilimumab) • ABP 206 (nivolumab biosimilar)"],"overall_status":"Suspended","enrollment":" Enrollment 37","initiation":"Initiation: 12/24/2020","start_date":" 12/24/2020","primary_txt":" Primary completion: 05/31/2025","primary_completion_date":" 05/31/2025","study_txt":" Completion: 05/31/2025","study_completion_date":" 05/31/2025","last_update_posted":"2025-02-17"},{"id":"734fb6ec-a3fe-4fc6-b873-fdb6107121be","acronym":"KEYNOTE-B21","url":"https://clinicaltrials.gov/study/NCT04634877","created_at":"2021-01-19T20:37:16.755Z","updated_at":"2025-02-25T14:08:01.972Z","phase":"Phase 3","brief_title":"Study of Pembrolizumab (MK-3475) in Combination With Adjuvant Chemotherapy With or Without Radiotherapy in Participants With Newly Diagnosed Endometrial Cancer After Surgery With Curative Intent (MK-3475-B21 / KEYNOTE-B21 / ENGOT-en11 / GOG-3053)","source_id_and_acronym":"NCT04634877 - KEYNOTE-B21","lead_sponsor":"Merck Sharp \u0026 Dohme LLC","biomarkers":" TP53","pipe":" | ","alterations":" TP53 mutation","tags":["TP53"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • cisplatin • carboplatin • paclitaxel • docetaxel"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 990","initiation":"Initiation: 01/10/2021","start_date":" 01/10/2021","primary_txt":" Primary completion: 05/31/2026","primary_completion_date":" 05/31/2026","study_txt":" Completion: 05/31/2026","study_completion_date":" 05/31/2026","last_update_posted":"2025-02-17"},{"id":"be1f4791-7f5f-42b3-86ee-a6bfee99acee","acronym":"ASSURE","url":"https://clinicaltrials.gov/study/NCT04008706","created_at":"2021-01-18T19:41:49.844Z","updated_at":"2025-02-25T14:07:28.508Z","phase":"Phase 3","brief_title":"Acalabrutinib Safety Study in Untreated and Relapsed or Refractory Chronic Lymphocytic Leukemia Patients","source_id_and_acronym":"NCT04008706 - ASSURE","lead_sponsor":"AstraZeneca","biomarkers":" TP53 • CD20 • IGH • CD5 • FCER2","pipe":" | ","alterations":" Chr del(17p) • Chr del(11q) • IGH mutation","tags":["TP53 • CD20 • IGH • CD5 • FCER2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Chr del(17p) • Chr del(11q) • IGH mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Calquence (acalabrutinib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 552","initiation":"Initiation: 09/17/2019","start_date":" 09/17/2019","primary_txt":" Primary completion: 09/01/2025","primary_completion_date":" 09/01/2025","study_txt":" Completion: 09/01/2025","study_completion_date":" 09/01/2025","last_update_posted":"2025-02-17"},{"id":"2487ddb2-7738-4021-b64c-94036379e85b","acronym":"CHAMP","url":"https://clinicaltrials.gov/study/NCT04709276","created_at":"2021-01-19T20:52:08.240Z","updated_at":"2025-02-25T14:29:51.192Z","phase":"Phase 2","brief_title":"A Study of Chemoimmunotherapy for the Treatment of Men With Neuroendocrine or Aggressive Variant Metastatic Prostate Cancer","source_id_and_acronym":"NCT04709276 - CHAMP","lead_sponsor":"Andrew J. Armstrong, MD","biomarkers":" TP53 • PTEN • RB1 • SYP","pipe":" | ","alterations":" LDH elevation","tags":["TP53 • PTEN • RB1 • SYP"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e LDH elevation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • Yervoy (ipilimumab) • carboplatin • cabazitaxel"],"overall_status":"Recruiting","enrollment":" Enrollment 43","initiation":"Initiation: 06/07/2021","start_date":" 06/07/2021","primary_txt":" Primary completion: 12/01/2025","primary_completion_date":" 12/01/2025","study_txt":" Completion: 06/01/2028","study_completion_date":" 06/01/2028","last_update_posted":"2025-02-14"},{"id":"38aae3c4-f386-4a60-a95e-c6b46ee44656","acronym":"","url":"https://clinicaltrials.gov/study/NCT05656248","created_at":"2022-12-19T14:58:46.031Z","updated_at":"2025-02-25T14:41:44.924Z","phase":"Phase 2","brief_title":"Study of CPX-351 (VYXEOS) in Individuals \u003c 22 Years With Secondary Myeloid Neoplasms","source_id_and_acronym":"NCT05656248","lead_sponsor":"St. Jude Children's Research Hospital","biomarkers":" TP53 • NF1 • RUNX1 • ETV6 • CEBPA • CD4 • MECOM • GATA2 • ANKRD26","pipe":"","alterations":" ","tags":["TP53 • NF1 • RUNX1 • ETV6 • CEBPA • CD4 • MECOM • GATA2 • ANKRD26"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Vyxeos (cytarabine/daunorubicin liposomal formulation)"],"overall_status":"Recruiting","enrollment":" Enrollment 25","initiation":"Initiation: 01/17/2023","start_date":" 01/17/2023","primary_txt":" Primary completion: 08/01/2025","primary_completion_date":" 08/01/2025","study_txt":" Completion: 08/01/2028","study_completion_date":" 08/01/2028","last_update_posted":"2025-02-14"},{"id":"7d78cd12-55c9-4664-9e5c-f58906c32c60","acronym":"","url":"https://clinicaltrials.gov/study/NCT06311227","created_at":"2024-03-15T17:37:14.823Z","updated_at":"2025-02-25T14:42:47.183Z","phase":"Phase 2","brief_title":"Venetoclax for the Treatment of Patients With Relapsed Hairy Cell Leukemia","source_id_and_acronym":"NCT06311227","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" BRAF • TP53","pipe":" | ","alterations":" TP53 mutation","tags":["BRAF • TP53"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Venclexta (venetoclax)"],"overall_status":"Recruiting","enrollment":" Enrollment 20","initiation":"Initiation: 05/15/2025","start_date":" 05/15/2025","primary_txt":" Primary completion: 05/20/2027","primary_completion_date":" 05/20/2027","study_txt":" Completion: 05/20/2027","study_completion_date":" 05/20/2027","last_update_posted":"2025-02-14"},{"id":"c9d1a579-ede0-4060-a970-738063622323","acronym":"","url":"https://clinicaltrials.gov/study/NCT03654716","created_at":"2021-01-18T17:56:08.387Z","updated_at":"2025-02-25T14:40:01.342Z","phase":"Phase 1","brief_title":"Phase 1 Study of the Dual MDM2/MDMX Inhibitor ALRN-6924 in Pediatric Cancer","source_id_and_acronym":"NCT03654716","lead_sponsor":"Dana-Farber Cancer Institute","biomarkers":" TP53 • MDM2 • TET2 • SMARCB1 • PPM1D","pipe":" | ","alterations":" TP53 wild-type • TET2 mutation","tags":["TP53 • MDM2 • TET2 • SMARCB1 • PPM1D"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 wild-type • TET2 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cytarabine • sulanemadlin (ALRN-6924)"],"overall_status":"Completed","enrollment":" Enrollment 21","initiation":"Initiation: 11/01/2018","start_date":" 11/01/2018","primary_txt":" Primary completion: 07/17/2023","primary_completion_date":" 07/17/2023","study_txt":" Completion: 07/17/2023","study_completion_date":" 07/17/2023","last_update_posted":"2025-02-14"}]